| 11/16/2026 11:56 AM | Contineum Therapeutics (1855175) Subject Janus Henderson Group Ltd. (1274173) Filed by | Form SCHEDULE 13G/A | |
| 11/16/2026 5:01 AM | BALYASNY ASSET MANAGEMENT L.P. (1218710) Filed by Contineum Therapeutics (1855175) Subject | Form SCHEDULE 13G/A | |
| 11/06/2026 9:20 AM | Contineum Therapeutics (1855175) Subject Johnson & Johnson Innovation - JJDC, Inc. (924020) Filed by | Form SCHEDULE 13G/A | |
| 11/04/2026 3:22 PM | Contineum Therapeutics (1855175) Subject Lorrain Daniel S. (1861550) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 11/03/2026 3:08 PM | Contineum Therapeutics (1855175) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/28/2026 3:16 PM | Contineum Therapeutics (1855175) Subject Squadron Capital Management LLC (2050709) Filed by | Form SCHEDULE 13G | |
| 10/28/2026 12:06 PM | Contineum Therapeutics (1855175) Subject FRANKLIN TEMPLETON INC (38777) Filed by | Form SCHEDULE 13G/A | |
| 10/22/2026 3:15 PM | Contineum Therapeutics (1855175) Subject Trails Edge Capital Partners, LP (2077247) Filed by | Form SCHEDULE 13G | |
| 10/01/2026 3:21 PM | Contineum Therapeutics (1855175) Subject Lorrain Daniel S. (1861550) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 09/14/2026 3:07 PM | Contineum Therapeutics (1855175) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 09/08/2026 5:08 PM | Contineum Therapeutics (1855175) Issuer Stengone Carmine N. (1861519) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for CTNM and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Contineum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 09/08/2026 3:28 PM | Contineum Therapeutics (1855175) Subject Stengone Carmine N. (1861519) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 09/01/2026 3:35 PM | Contineum Therapeutics (1855175) Subject Lorrain Daniel S. (1861550) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/14/2026 5:02 AM | BALYASNY ASSET MANAGEMENT L.P. (1218710) Filed by Contineum Therapeutics (1855175) Subject | Form SCHEDULE 13G/A | |
| 08/03/2026 5:14 PM | Contineum Therapeutics (1855175) Issuer Stengone Carmine N. (1861519) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/03/2026 3:18 PM | Contineum Therapeutics (1855175) Subject Lorrain Daniel S. (1861550) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/03/2026 3:19 PM | Contineum Therapeutics (1855175) Subject Stengone Carmine N. (1861519) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/30/2026 3:11 PM | Contineum Therapeutics (1855175) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 07/17/2026 4:10 PM | Contineum Therapeutics (1855175) Subject MILLENNIUM MANAGEMENT LLC (1273087) Filed by | Form SCHEDULE 13G/A | |
| 07/13/2026 3:15 PM | Contineum Therapeutics (1855175) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 07/10/2026 4:20 PM | Contineum Therapeutics (1855175) Issuer Lorrain Daniel S. (1861550) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/08/2026 5:49 PM | Contineum Therapeutics (1855175) Issuer Stengone Carmine N. (1861519) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/08/2026 3:39 PM | Contineum Therapeutics (1855175) Subject Stengone Carmine N. (1861519) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/02/2026 4:47 PM | Contineum Therapeutics (1855175) Issuer Lorrain Daniel S. (1861550) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/01/2026 6:04 PM | Contineum Therapeutics (1855175) Issuer Stengone Carmine N. (1861519) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/01/2026 6:04 PM | Contineum Therapeutics (1855175) Issuer Watkins Tim (2065965) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/01/2026 3:34 PM | Contineum Therapeutics (1855175) Subject Lorrain Daniel S. (1861550) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/30/2026 3:38 PM | Contineum Therapeutics (1855175) Subject Lorrain Daniel S. (1861550) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 4:42 PM | Boyce Sarah (1629383) Reporting Contineum Therapeutics (1855175) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/26/2026 4:43 PM | Brady Todd R. (1767644) Reporting Contineum Therapeutics (1855175) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/26/2026 4:43 PM | Contineum Therapeutics (1855175) Issuer Ignelzi Troy A. (1579829) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/26/2026 4:44 PM | Contineum Therapeutics (1855175) Issuer Schimmelpennink Evert B. (1713795) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/26/2026 4:44 PM | Contineum Therapeutics (1855175) Issuer Ware Olivia C (1663771) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/26/2026 4:45 PM | Contineum Therapeutics (1855175) Issuer Lyons-Williams Lori (1693564) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/26/2026 4:46 PM | Contineum Therapeutics (1855175) Issuer Miralles Gines Diego (1773413) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/26/2026 3:48 PM | Contineum Therapeutics (1855175) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/01/2026 5:08 PM | Contineum Therapeutics (1855175) Issuer Lorrain Daniel S. (1861550) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/01/2026 3:19 PM | Contineum Therapeutics (1855175) Subject Lorrain Daniel S. (1861550) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/15/2026 5:41 AM | BALYASNY ASSET MANAGEMENT L.P. (1218710) Filed by Contineum Therapeutics (1855175) Subject | Form SCHEDULE 13G | |
| 05/01/2026 4:42 PM | Contineum Therapeutics (1855175) Issuer Lorrain Daniel S. (1861550) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/01/2026 3:47 PM | Contineum Therapeutics (1855175) Subject Lorrain Daniel S. (1861550) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
I'm handing you this stock today (Ad) Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company.
Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty.
Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout. Download this free stock pick before December 8th arrives |
| 04/17/2026 3:42 PM | Contineum Therapeutics (1855175) Subject MILLENNIUM MANAGEMENT LLC (1273087) Filed by | Form SCHEDULE 13G | |
| 04/06/2026 4:43 PM | Contineum Therapeutics (1855175) Issuer Lorrain Daniel S. (1861550) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/06/2026 3:33 PM | Contineum Therapeutics (1855175) Subject Lorrain Daniel S. (1861550) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/05/2026 3:09 PM | Contineum Therapeutics (1855175) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/05/2026 3:15 PM | Contineum Therapeutics (1855175) Filer | Form 424B5 | |
| 03/02/2026 5:28 PM | Contineum Therapeutics (1855175) Issuer Watkins Tim (2065965) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/02/2026 5:30 PM | Contineum Therapeutics (1855175) Issuer Lorrain Daniel S. (1861550) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/17/2026 5:28 AM | BALYASNY ASSET MANAGEMENT L.P. (1218710) Filed by Contineum Therapeutics (1855175) Subject | Form SCHEDULE 13G | |
| 01/30/2026 3:52 PM | Contineum Therapeutics (1855175) Issuer Watkins Tim (2065965) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/30/2026 3:54 PM | Contineum Therapeutics (1855175) Issuer Lorrain Daniel S. (1861550) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/30/2026 3:56 PM | Contineum Therapeutics (1855175) Issuer Stengone Carmine N. (1861519) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/30/2026 3:57 PM | Contineum Therapeutics (1855175) Issuer Slover Peter T (1468012) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/29/2026 9:38 AM | Contineum Therapeutics (1855175) Subject FRANKLIN RESOURCES INC (38777) Filed by | Form SCHEDULE 13G/A | |
| 01/26/2026 3:06 PM | Contineum Therapeutics (1855175) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/06/2026 3:16 PM | Contineum Therapeutics (1855175) Issuer Lorrain Daniel S. (1861550) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/05/2026 3:42 PM | Contineum Therapeutics (1855175) Subject Lorrain Daniel S. (1861550) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/30/2025 3:10 PM | Contineum Therapeutics (1855175) Issuer Lorrain Daniel S. (1861550) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/30/2025 3:12 PM | Contineum Therapeutics (1855175) Issuer Watkins Tim (2065965) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/29/2025 3:25 PM | Contineum Therapeutics (1855175) Subject Watkins Tim (2065965) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/23/2025 3:20 PM | Contineum Therapeutics (1855175) Subject Lorrain Daniel S. (1861550) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 12/12/2025 4:00 PM | Contineum Therapeutics (1855175) Filer | Form 424B5 | |
| 11/20/2025 3:07 PM | Contineum Therapeutics (1855175) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |